eFFECTOR Therapeutics, Inc.
EFTR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $3,553 | $1,430 | $42,000 |
| % Growth | -100% | 148.5% | -96.6% | – |
| Cost of Goods Sold | $111 | $53 | $24 | $0 |
| Gross Profit | -$111 | $3,500 | $1,406 | $42,000 |
| % Margin | – | 98.5% | 98.3% | 100% |
| R&D Expenses | $22,919 | $23,313 | $19,956 | $21,832 |
| G&A Expenses | $10,925 | $12,643 | $13,371 | $4,349 |
| SG&A Expenses | $10,925 | $12,643 | $13,371 | $4,349 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$53 | -$24 | $0 |
| Operating Expenses | $33,844 | $35,903 | $33,303 | $26,181 |
| Operating Income | -$33,844 | -$32,403 | -$33,327 | $15,819 |
| % Margin | – | -912% | -2,330.6% | 37.7% |
| Other Income/Exp. Net | -$1,967 | $9,738 | $0 | -$1,257 |
| Pre-Tax Income | -$35,811 | -$22,665 | $15,798 | $14,562 |
| Tax Expense | $0 | -$9,738 | $0 | $351 |
| Net Income | -$35,811 | -$12,927 | $15,798 | $14,211 |
| % Margin | – | -363.8% | 1,104.8% | 33.8% |
| EPS | -16.37 | -7.85 | 9.78 | 0.28 |
| % Growth | -108.5% | -180.3% | 3,392.9% | – |
| EPS Diluted | -16.37 | -7.85 | 9.78 | 0.1 |
| Weighted Avg Shares Out | 2,187 | 1,647 | 1,616 | 599 |
| Weighted Avg Shares Out Dil | 2,187 | 1,647 | 1,616 | 599 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,947 | $439 | $6 | $67 |
| Interest Expense | $0 | $2,251 | $1,764 | $1,333 |
| Depreciation & Amortization | $111 | $53 | $24 | $160 |
| EBITDA | -$32,781 | -$20,361 | $17,586 | $16,055 |
| % Margin | – | -573.1% | 1,229.8% | 38.2% |